FDA Allows Juno To Resume Anticancer Treatment Study Juno Therapeutics' cancer study has now been allowed to resume a week after its clinical trials were suspended by the FDA. The trials will continue without a certain chemotherapy drug. by Alyssa Navarro
Researchers Achieve Record Data Transmission Speed, 4.5 Million Times Faster Than Average Home Broadband